Urovant Sciences and Genmab reported disappointing clinical trial announcements.
Following a mid-stage flop, Ironwood and AbbVie discontinued the development of an experimental drug aimed at the treatment of abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D).
Gilead Sciences and South San Francisco-based Second Genome forged a four-year strategic collaboration worth more than $1.5 billion that will boost chances to discover and develop new targets and drug candidates for the treatment of inflammatory bowel disease through microbiome research.
Copenhagen-based Zealand Pharma announced a bid to buy substantially all the assets from New Jersey-based Valeritas in $23 million in cash and taking on certain liabilities.
Oldwick, New Jersey-based Provention Bio’s PRV-6527, which was licensed from Johnson & Johnson company Janssen, failed in a mid-stage clinical trial.
Takeda Pharmaceutical Company Limited announced further results from the VARSITY study, which demonstrated the superiority of the gut-selective biologic vedolizumab (Entyvio) to the anti-tumor necrosis factor-alpha biologic adalimumab (Humira) in achieving the primary endpoint of clinical remission at week 52 in patients with moderately to severely active ulcerative colitis, were published in The New England Journal of Medicine (NEJM).
Japan’s Takeda Pharmaceutical presented more data from the company’s Phase IIIb head-to-head VARSITY clinical trial of Entyvio compared to AbbVie’s Humira in ulcerative colitis.
Takeda Pharmaceutical Company Limited announced results from the Phase 3b head-to-head VARSITY study which demonstrated that the gut-selective biologic vedolizumab (Entyvio) was superior to the anti-tumor necrosis factor-alpha biologic adalimumab (Humira) in achieving clinical remission in patients with moderately to severely active ulcerative colitis at week 52.
For the 11th year, Med Ad News selected new Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
